Purdue Pharma L.p.

Purdue Pharmaceuticals L.p.

The P.f. Laboratories, Inc.

Euro-celtique S.a.

Other

Hospira, Inc.

Javelin Pharmaceuticals, Inc.

Curtis Wright

Benjamin Oshlack

Christopher D Breder

J David Haddox

Robert D Colucci

Derek Allan Prater

JDavid Haddox

Anthony E Carpanzano

Fred H Mermelstein

Daniel B Carr

Charles Wray

Ahmed El-Tahtawy

Raymond Sanchez

Richard S Sackler

Stephen A Howard

Ihor Shevchuk

Thomas J Bradley

Lino Tavares

Bruce E Reidenberg

Chris Breder

James P Cassidy

Derek Prater

David J Haddox

Mark A Alfonso

Rampurna Prasad Gullapalli

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Pharmaceutical formulation containing gelling agent

The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C/Coxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.

Oxycodone formulations

Oral dosage forms containing an opioid antagonist in a sequestered form are described. The opioid antagonist is sequestered such that it is not released or substantially not released in the gastrointestinal tract from the dosage form which is administered orally intact. However, when the dosage form is chewed, crushed, heated or dissolved in a solvent, and then administered orally, intranasally, parenterally or sublingually, the opioid antagonist is released and at least partially blocks effects of the opioid agonist.

Tamper resistant oral opioid agonist formulations

Cable vibration damper

Disclosed are oral dosage forms, comprising (i) a therapeutically effective amount of an opioid agonist; (ii) an opioid antagonist in releasable form; and (iii) a sequestered opioid antagonist which is not released when the dosage form is administered intact, and methods thereof.

Opioid agonist formulations with releasable and sequestered antagonist

Growing community of inventors

Rockport, MA, United States of America

Curtis Wright